Clinical Trial Update: Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing safety, tolerability, pharmacokinetics, and 5-HT1A receptor occupancy in Alzheimer's disease has been completed. The sponsor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED